PNOC041NCT07226453
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 10 → 13 locations
- Minor Study sites revised (12)
- Minor Study sites: 10 to 12
- Notable Eligibility criteria revised
- Study description revised
- Site details revised at 3 of 10 sites
- Minor Study sites revised (10)v13
- Minor Site details revised at 1 of 10 sitesv12
- Minor Trial sites expanded: 5 → 10 locationsv11
- Minor Site details revised at 1 of 5 sitesv10
- Minor Study sites: 3 to 5v9
- Minor Study sites: 1 to 3v8
- Notable Eligibility criteria expanded, about 32 wordsv7
- Notable Recruitment opened
- Start date changed from estimate of Jun 1, 2026 to May 5, 2026
- Site details revised
- Minor Start date: May 4, 2026 to Jun 1, 2026v5
- Notable Start date: Mar 4, 2026 to May 4, 2026
- Trial status changed: Recruiting → Not Yet Recruiting
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 28, 2026 to Mar 4, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Participants will each receive daily oral metformin with a weekly schedule starting at 250 mg/m\^2 twice a day (BID) for the first week, then increasing to 500 mg/m\^2 BID for week 2, 1000 mg/m\^2 BID for week 3, and then 1666 mg/m\^2 BID for week 4-6 prior to planned surgery. Participants with no measurable disease following surgical intervention may either go off treatment or continue metformin at the physician's discretion. Participants have the option of continuing on the efficacy phase of the study without undergoing planned surgery no demonstrated progressive disease on pre-surgery MRI AND if the family opts to continue treatment with metformin without undergoing surgical resection of the tumor. Participants with measurable tumor by RAPNO criteria following surgery may continue onto efficacy phase and receive maintenance metformin until disease progression or till there are unacceptable adverse event(s).
Participants with recurrent or progressive PFA ependymoma that have failed upfront surgery and radiation will receive daily oral metformin until disease progression or till there are unacceptable adverse event(s). Disease response will be assessed by MRI imaging using RAPNO criteria. Participants already enrolled on the TV phase may enroll in this phase if they have measurable disease post-surgery. Treatment may continue until disease progression or until there are unacceptable adverse event(s).
Drugs: Metformin
Procedures: Planned Surgical Resection, Magnetic Resonance Imaging (MRI), Specimen Collection, MR spectroscopy (MRS)
Sites
13 sites in 2 countries
United States 12, Brazil 1